- Active not recruitingPHASE2
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
This study looks at using detailed tumour gene testing to guide treatment for advanced breast cancer. It compares giving targeted drugs based on these tests with standard chemotherapy or immunotherapy for patients whose cancer has responded well to initial treatment.
For: Metastatic Breast CancerFrance - Active not recruitingPHASE3
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
This study compares a new treatment, TAR-200, with standard chemotherapy for a type of bladder cancer that has returned after initial treatment. It's for people who can't or won't have surgery to remove their bladder.
For: Non-Muscle Invasive Bladder NeoplasmsUnited States · Argentina · Belgium - RecruitingPhase I
A study to explore the best dose of mitomycin-c inside your eye during retinal detachment surgery
This study looks at the best dose of a medicine called Mitomycin-C (MMC) to use during eye surgery for serious retinal detachment. It aims to reduce scarring that can make the retina detach again, improving vision for patients.
For: Proliferative vitreoretinopathy in rhegmatogenous retinal detachmentUnited Kingdom - RecruitingPHASE3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
This study compares a new treatment, TAR-210, with standard chemotherapy for high-risk bladder cancer that hasn't spread to the muscle. It aims to see which treatment best prevents the cancer from returning or getting worse.
For: Non-Muscle Invasive Bladder NeoplasmsUnited States · Argentina · Belgium - RecruitingPHASE3
Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)
This study looks at two different doses of heated chemotherapy (HIPEC) for a rare cancer called PMP. We want to see if the lower dose, given for a shorter time, works just as well as the higher dose, which could mean fewer side effects for patients.
For: Pseudomyxoma PeritoneiUnited Kingdom